Journals / Neurological sciences and neurophysiology (Online) / 2018 / Cilt: 35 - Sayı: 4

Impact of a new migraine-specific comorbidity index on prognosis: A methodology study

Pages
183–188
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Lastly, according to the results obtained from the GBTM analysis and physicians viewpoints, a migraine-specific comorbidity index was developed and validated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Abstract Objective: To develop and validate a comorbidity index to estimate the prognosis of migraine, defined as the severity of headache measured longitudinally in a heterogeneous population.
📊
Key Findings & Data:Methods: The study data were collected from a computer-based Turkish Headache Database with 15-year’s follow-up data.
💡
Conclusion & Impact:Lastly, according to the results obtained from the GBTM analysis and physicians viewpoints, a migraine-specific comorbidity index was developed and validated.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Abstract Objective: To develop and validate a comorbidity index to estimate the prognosis of migraine, defined as the severity of headache measured longitudinally in a heterogeneous population. Methods: The study data were collected from a computer-based Turkish Headache Database with 15-year’s follow-up data. The primary outcome was defined as the severity of headache [visual analog scale (VAS)] obtained from baseline to the 7th visit. The procedure was multistage: First, latent subgroups were determined using group-based trajectory modeling (GBTM) because the change in outcomes over time were different for each patient. Second, group-based trajectory modeling analysis was applied with the purpose of understanding how to evaluate comorbidities. Lastly, according to the results obtained from the GBTM analysis and physicians viewpoints, a migraine-specific comorbidity index was developed and validated. Results: Out of all weighting methods to evaluate comorbidities, the three-group model and quadratic form of all groups fitted the data best. After deciding the number of groups and functional form, the information criteria and minimum group percentage of the weighting methods were compared. The best method was the posterior probabilities obtained from latent class analysis (LCA) taken as weights. At the same time, age was effective in the separation of the second and third groups from the first group for severity (p=0.047, p=0.007). Sex difference had no effect on the prognosis of migraine (p=0.99, p=0.16). Conclusion: According to these results, an index formula was developed to evaluate the effect of covariates on migraine severity prognosis. A migraine-specific comorbidity index called the Migraine Comorbidity Index (MCI) was created by applying the formula.

🔖

Cite This Article

YILDIRIM, D. D., TAŞDELEN, B., ULUDÜZ, D., ÖZGE, A., YOLOĞLU, S. (2018). Impact of a new migraine-specific comorbidity index on prognosis: A methodology study. Neurological sciences and neurophysiology (Online), Cilt: 35 - Sayı: 4, 183–188. https://ajindex.com/articles/290556

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chron Dis 1970; 23: 455-468. [CrossRef] de Groot V, Beckerman H, Lankhorst G, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of avaliable methods. J Clin Epidemiol 2003; 56: 221-229. [CrossRef] Kaplan MH, Feinstein AR. The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974; 27: 387-404. [CrossRef] Sarfati D. Review of methods used to measure comorbidity in cancer populations: No gold standard exists. J Clin Epidemiol 2012; 65: 924-933. [CrossRef] Rozzini R, Sabatini T, Barbisoni P, Trabucchi M. How to measure comorbidity in elderly persons. J Clin Epidemiol 2004; 57: 321- 322. [CrossRef] Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383. [CrossRef] Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000; 36: 453-471. [CrossRef] Grunau GL, Sheps S, Goldner EM, Ratner PA. Specific comorbidity risk adjustment was a better predictor of 5-year acute myocardial infarction mortality than general methods. J Clin Epidemiol 2006; 59: 274-280. [CrossRef] Schera AI, Bigalb ME, Lipton RB. Comorbidity of migraine. Curr Opin Neurol 2005; 18: 305-310. [CrossRef] Wang SJ, Chen PK, Fuh, JL. Comorbidities of migraine. Front Neurol 2010; 1: 1-9. [CrossRef] Yildirim DD, Tasdelen B, Ozge A. The effect of co-morbidity on the modeling of migraine prognosis. XVIII. National and I. International Biostatistics Congress, Antalya, Turkey, 26-29 October 2016, pp.85. Nagin SD, Odgers CL. Group based trajectory modeling in clinical research. Annu Rev Clin Psychol 2010; 6: 109-138. [CrossRef] Nagin D. Group-based modeling of development. 1st ed. United States of America: Harvard Univ. Press, 2005, p.201. [CrossRef] Klabunde CN, Potosky AL, Legler JML, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53: 1258-1267. [CrossRef] Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1-211.
  2. Fleming ST, Pearce KA, McDavid K, Pavlov D. The development and validation of a comorbidity index for prostate cancer among black men. J Clin Epidemiol 2003; 56: 1064-1075. [CrossRef] Tooth L, Hockey R, Byles J, Dobson A. We